Vaccination and autoimmune rheumatic diseases

Area of Science:

• Rheumatology
• Immunology
• Infectious Diseases

Background:

• Patients with autoimmune rheumatic diseases face a higher risk of infections.
• Concerns regarding vaccine safety and immunogenicity have historically limited their use in this population.
• Causal links between vaccinations and the onset of rheumatic diseases are not established.

Purpose of the Study:

• To evaluate the safety and immunogenicity of vaccines in patients with autoimmune rheumatic diseases.
• To address concerns about vaccine use in immunocompromised patients.
• To provide evidence-based recommendations for vaccine administration in rheumatology patients.

Main Methods:

• Review of studies on influenza and pneumococcal vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis.
• Analysis of safety data, including adverse events and disease flares.
• Assessment of serological responses to vaccines, particularly in patients on immunosuppressive agents and TNFalpha blocking therapies.

Main Results:

• Influenza and pneumococcal vaccines are generally safe and serologically effective in patients with systemic lupus erythematosus.
• These vaccines are considered safe and immunogenic in most patients with rheumatoid arthritis.
• Inadequate immune responses may occur in patients receiving immunosuppressive agents.
• Treatment with TNFalpha blocking agents did not appear to negatively impact the immune response to vaccines.

Conclusions:

• Vaccination with influenza and pneumococcal vaccines is recommended for patients with autoimmune rheumatic diseases.
• The benefits of vaccination in preventing infections outweigh potential risks.
• Further research may be needed to optimize vaccine response in patients on potent immunosuppressive therapies.